Breaking News

Medivir, Daewoong Discontinue Hep B Alliance

September 6, 2013

MIV-210 fails to eradicate HBV

Medivir AB and Daewoong Pharmaceutical Co. Ltd. have decided to discontinue development of hepatitis B compound, MIV-210, based on a joint decision.
 
Under the collaboration Daewoong was responsible for R&D. While MIV-210 demonstrated competitive antiviral activity, like other drugs of this class, it did not completely eradicate HBV. Taking into consideration the commercial environment for HBV drugs, with the current standard of care approaching generic status, a robust cure profile is needed, which would require combination with other drugs.
 
“In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210”, said Maris Hartmanis, chief executive officer, Medivir AB.

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.